var data={"title":"Clopidogrel: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clopidogrel: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5930?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clopidogrel-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clopidogrel: Patient drug information&quot;</a> and <a href=\"topic.htm?path=clopidogrel-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Clopidogrel: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10072956\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP-450) system, principally CYP2C19. Clopidogrel at recommended doses forms less of the active metabolite and has a reduced effect on platelet activity in patients who are homozygous for nonfunctional alleles of the CYP2C19 genes (termed &ldquo;CYP2C19 poor metabolizers&rdquo;). Tests are available to identify patients who are CYP2C19 poor metabolizers. Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153626\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Plavix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50667916\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Plavix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153658\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiplatelet Agent;</li>\n      <li>\n        Antiplatelet Agent, Thienopyridine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153630\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute coronary syndrome (ACS):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Unstable angina, non-ST-segment elevation myocardial infarction (UA/NSTEMI) (also referred to as NSTE-ACS):</i> Initial: 300 mg or 600 mg loading dose, followed by 75 mg once daily for up to 12 months in combination with aspirin, followed by aspirin indefinitely (ACC/AHA [Amsterdam 2014]). <b>Note:</b> If patient is to undergo PCI, see <i>Percutaneous coronary intervention (PCI) for acute coronary syndrome</i> dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy (in combination with aspirin and appropriate anticoagulant) (ACCF/AHA [O'Gara 2013]):</i> <b>Note: </b> If patient is to undergo primary PCI, see <i>Percutaneous coronary intervention (PCI) for acute coronary syndrome</i> dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Age &le;75 years: Loading dose of 300 mg followed by 75 mg once daily for at least 14 days up to 1 year (in the absence of bleeding).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Age &gt;75 years: 75 mg once daily (no loading dose) for at least 14 days up to 1 year (in the absence of bleeding).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Percutaneous coronary intervention (PCI) for acute coronary syndrome (eg, NSTE-ACS or STEMI) (off-label use):</i> 600 mg (loading dose) given as early as possible before or at the time of PCI, followed by 75 mg once daily (in combination with aspirin) for at least 12 months (bare metal or drug-eluting stent) (ACC/AHA [Amsterdam 2014]); ACC/AHA [Levine 2016]; ACCF/AHA/SCAI [Levine 2011]; ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>PCI after fibrinolytic therapy</i> (ACCF/AHA [O'Gara 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fibrinolytic administered <b>with</b> a loading dose of clopidogrel: Continue 75 mg once daily and do not administer an additional loading dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fibrinolytic administered within previous 24 hours <b>without</b> a loading dose of clopidogrel: Administer 300 mg loading dose before or at the time of PCI.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fibrinolytic administered more than 24 hours ago without a loading dose of clopidogrel: Administer 600 mg loading dose before or at the time of PCI.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Higher versus standard maintenance dosing: May consider a maintenance dose of 150 mg once daily for 6 days, then 75 mg once daily thereafter in patients not at high risk for bleeding (CURRENT-OASIS 7 Investigators 2010); however, in another study, in patients with high on-treatment platelet reactivity, the use of 150 mg once daily for 6 months did not demonstrate a difference in 6-month incidence of death from cardiovascular causes, nonfatal MI, or stent thrombosis compared to standard dose therapy (Price 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of clopidogrel (in combination with aspirin) after stent placement for ACS: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Duration of Dual Antiplatelet Therapy (DAPT) guidelines, at least 12 months of a P2Y12 inhibitor (eg, clopidogrel) is recommended for those with ACS receiving either stent type (bare metal [BMS] or drug eluting stent [DES]). The DAPT score may be useful in determining whether to prolong or extend DAPT in patients with stent placement (Yeh 2016). In patients with DES placement with a high risk of bleeding or significant overt bleeding on DAPT, it may be reasonable to discontinue clopidogrel after 6 months of therapy (ACC/AHA [Levine 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CYP2C19 poor metabolizers (ie, <i>CYP2C19*2</i> or <i>*3 </i> carriers): Although routine genetic testing is not recommended in patients treated with clopidogrel undergoing PCI, testing may be considered to identify poor metabolizers who would be at risk for poor outcomes while receiving clopidogrel; if identified, these patients may be considered for an alternative P2Y<sub>12</sub> inhibitor (Levine 2011). An appropriate regimen for this patient population has not been established in clinical outcome trials. Although a 600 mg loading dose, followed by 150 mg once daily produced greater active metabolite exposure and antiplatelet response compared to the 300 mg/75 mg regimen, it does not appear that this dosing strategy improves outcomes for this patient population (Price 2011; Simon 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation, primary prevention of thromboembolism (off-label use):</b> Oral: 75 mg once daily (in combination with aspirin 75 to 100 mg once daily) (ACTIVE Investigators 2009). <b>Note: </b>Oral anticoagulation is preferred; clopidogrel and aspirin may be used in patients who cannot take oral anticoagulation and are at low bleeding risk (ACCP [You 2012]). The patient with an elevated bleeding risk who is not a candidate for oral anticoagulation would not be a candidate for dual antiplatelet therapy given the comparable risk of bleeding events (Connolly 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Carotid artery stenosis, symptomatic (including recent carotid endarterectomy) (off-label use):</b> Oral: 75 mg once daily (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coronary artery bypass graft surgery (secondary prevention) (off-label use) (AHA [Kulik 2015]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Following off-pump CABG:</i> 75 mg once daily (in combination with aspirin) for 1 year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Aspirin-allergic or -intolerant patients:</i> 75 mg once daily; continue indefinitely</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coronary artery disease (CAD), established (off-label use):</b> Oral: 75 mg once daily. <b>Note:</b> Established CAD defined as patients 1-year post ACS, with prior revascularization, coronary stenosis &gt;50% by angiogram, and/or evidence for cardiac ischemia on diagnostic testing (includes patients after the first year post-ACS and/or with prior CABG surgery) (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention (PCI), non-acute coronary syndrome (ie, stable ischemic heart disease) (off-label use):</b> 600 mg (loading dose) given as early as possible before or at the time of PCI, followed by 75 mg once daily (in combination with aspirin) for at least 1 month (bare metal stent) or for at least 6 months (drug-eluting stent) (ACC/AHA [Levine 2016]; ACCF/AHA/SCAI [Levine 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      Duration of clopidogrel (in combination with aspirin) after stent placement for stable ischemic heart disease (SIHD): Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to the ACC/AHA Duration of Dual Antiplatelet Therapy (DAPT) guidelines, those receiving a newer generation DES, at least 6 months of clopidogrel therapy is recommended. Those receiving a BMS should be given clopidogrel for a minimum of 1 month. The DAPT score may be useful in determining whether to prolong or extend DAPT in patients with stent placement (Yeh 2016). In patients with DES placement with a high risk of bleeding or significant overt bleeding on DAPT, it may be reasonable to discontinue clopidogrel after 3 months of therapy (ACC/AHA [Levine 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral artery percutaneous transluminal angioplasty (with or without stenting) or peripheral artery bypass graft surgery, postprocedure (off-label use):</b> Oral: 75 mg once daily. <b>Note:</b> For below-knee bypass graft surgery with prosthetic grafts, combine with aspirin 75-100 mg/day (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recent MI, recent stroke, or established peripheral arterial disease (PAD):</b> Oral: 75 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Guideline recommendations regarding concomitant therapy and durations of therapy (off-label):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Minor ischemic stroke or TIA, secondary prevention:</i> The combination of clopidogrel and aspirin might be considered within 24 hours of a minor ischemic stroke or TIA and continued for 21 days (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intracranial atherosclerosis (70% to 99% stenosis of a major intracranial artery), secondary prevention: </i>The combination of clopidogrel and aspirin for 90 days is recommended in patients with recent stroke/TIA (within 30 days) due to severe stenosis [70% to 99%]) (AHA/ASA [Kernan 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>PAD:</i> Clopidogrel is recommended as an alternative to aspirin or in conjunction with aspirin for those who are not at an increased risk of bleeding but are of high cardiovascular risk. These recommendations also pertain to those with intermittent claudication or critical limb ischemia, prior lower extremity revascularization, or prior amputation for lower extremity ischemia (ACCF/AHA [Rooke 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Secondary prevention of cardioembolic stroke (patient not candidate for oral anticoagulation)</i>: The combination of clopidogrel and aspirin is recommended (ACCP [Guyatt 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary prevention of cardiovascular disease (patients with diabetes and an aspirin allergy) (off-label use):</b> Oral: 75 mg once daily (ADA 2018)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153631\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153632\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment necessary (Basra 2011). <b>Note:</b> GFR stage 5 (ie, ESRD or an eGFR &lt;15 mL/minute) is associated with higher residual platelet reactivity with maintenance dosing (Muller 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153633\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153606\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plavix: 75 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153591\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11566548\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM243349.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV682FCKj3jdzG6SYXt3mbNdAw==&amp;TOPIC_ID=12303\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM243349.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9480379\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153608\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute coronary syndrome:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute ST-segment elevation myocardial infarction:</b> To reduce the rate of myocardial infarction and stroke in conjunction with aspirin in patients with acute ST-elevation MI (STEMI) who are to be managed medically.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Unstable angina/non-ST-segment elevation myocardial infarction:</b> To decrease the rate of MI and stroke in conjunction with aspirin in patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-ST-elevation myocardial infarction [UA/NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recent myocardial infarction, recent stroke, or established peripheral arterial disease:</b> To reduce the rate of MI and stroke in patients with a history of recent MI, recent stroke, or established peripheral arterial disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475278\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Adjunctive therapy to support reperfusion with primary percutaneous coronary intervention; Atrial fibrillation (primary prevention of thromboembolism); Coronary artery bypass graft (CABG) surgery (secondary prevention); Non-ST-elevation acute coronary syndromes in patients with allergy or major gastrointestinal intolerance to aspirin; Percutaneous coronary intervention (PCI), non-acute coronary syndrome (ie, stable ischemic heart disease); Peripheral artery percutaneous transluminal angioplasty; Secondary prevention of cardiovascular disease (patients with diabetes and an aspirin allergy); Symptomatic carotid artery stenosis (including recent carotid endarterectomy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153666\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Plavix may be confused with Elavil, Paxil, Pradax (Canada), Pradaxa</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153598\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs that may affect hemostasis, bleeding is associated with clopidogrel. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents that alter hemostasis and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Minor hemorrhage (4% to 5%), major hemorrhage (1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, acute generalized exanthematous pustulosis, acute hepatic failure, ageusia, agranulocytosis, anaphylactoid reaction, angioedema, aplastic anemia, arthralgia, arthritis, bronchospasm, bullous rash, colitis (including ulcerative or lymphocytic), confusion, diarrhea, DRESS syndrome, drug-induced hypersensitivity, duodenal ulcer, eczema, eosinophilic pneumonitis, erythema multiforme, erythematous rash, exfoliative dermatitis, fever, gastric ulcer, hallucination, headache, hemophilia A (acquired), hepatitis (noninfectious), hypersensitivity reaction, hypotension, increased serum creatinine, interstitial pneumonitis, intracranial hemorrhage, lichen planus, maculopapular rash, myalgia, pancreatitis, pancytopenia, pruritus, serum sickness, Stevens-Johnson syndrome, stomatitis, taste disorder, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, urticaria, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153611\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to clopidogrel or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Significant liver impairment or cholestatic jaundice; concomitant use of repaglinide.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153595\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Clopidogrel increases the risk of bleeding. Use is contraindicated in patients with active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage). Additional risk factors for bleeding include age &ge;75 years, propensity to bleed (eg, recent trauma or surgery, recent or recurrent GI bleeding, active peptic ulcer disease, severe hepatic impairment), body weight &lt;60 kg, CABG or other surgical procedure, concomitant use of medications that increase risk of bleeding (eg, warfarin, NSAIDs). Use with caution in patients with platelet disorders, bleeding disorders and/or at increased risk for bleeding. Bleeding should be suspected if patient becomes hypotensive after undergoing recent coronary angiography, PCI, CABG, or other surgical procedure even if overt signs of bleeding do not exist. It may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thienopyridine hypersensitivity: Because of structural similarities, cross-reactivity has been reported among the thienopyridines (clopidogrel, prasugrel, and ticlopidine); use with caution or avoid in patients with hypersensitivity or hematologic reactions to previous thienopyridine use. Use of clopidogrel is contraindicated in patients with hypersensitivity to clopidogrel. Although desensitization may be considered for mild-to-moderate hypersensitivity, do not desensitize patients with prior life-threatening allergic reactions to clopidogrel (eg, toxic epidermal necrolysis, exfoliative dermatitis, Stevens-Johnson syndrome, TTP) (Lokhandwala 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic thrombocytopenic purpura (TTP): Cases of TTP (usually occurring within the first 2 weeks of therapy), resulting in some fatalities, have been reported; urgent plasmapheresis is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lacunar stroke: In patients with recent lacunar stroke (within 180 days), the use of clopidogrel in addition to aspirin did not significantly reduce the incidence of the primary outcome of stroke recurrence (any ischemic stroke or intracranial hemorrhage) compared to aspirin alone; the use of clopidogrel in addition to aspirin did however increase the risk of major hemorrhage and the rate of all-cause mortality (SPS3 Investigators, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment (experience is limited).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2C19 poor metabolizers: <b>[US Boxed Warning]: </b><b>Effectiveness of clopidogrel results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the CYP-450 system, principally CYP2C19. In patients who are homozygous for nonfunctional alleles of the CYP2C19 genes (termed &ldquo;CYP2C19 poor metabolizers&rdquo;), clopidogrel at recommended doses forms less of the active metabolite and has a reduced effect on platelet activity. Tests are available to identify patients who are CYP2C19 poor metabolizers. Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers. </b>Genetic testing may be considered prior to initiating clopidogrel in patients at moderate or high risk for poor outcomes (eg, PCI in patients with extensive and/or very complex disease). The optimal dose for CYP2C19 poor metabolizers has yet to be determined. After initiation of clopidogrel, functional testing (eg, VerifyNow&reg; P2Y12 assay) may also be done to determine clopidogrel responsiveness (Holmes, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. In patients receiving dual antiplatelet therapy (aspirin plus P2Y<sub>12 </sub>receptor blocker [eg, clopidogrel, prasugrel, ticagrelor, ticlopidine]) or thienopyridine monotherapy, the thienopyridine should generally be resumed as soon as possible and at least within 7 days, taking into account control of bleeding and cardiovascular risk (aspirin should <i>not</i> be discontinued); however, dual antiplatelet therapy should <i>not </i>be discontinued in the 90 days post-acute coronary syndrome or 30 days post-coronary stenting (Strate 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: In patients undergoing elective surgery, consider discontinuing 5 days before surgery (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy; patient-specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations) (Grines 2007). Elective noncardiac surgery should not be performed in patients in whom dual antiplatelet therapy (DAPT) will need to be discontinued perioperatively within 30 days following bare metal stent (BMS) placement or within 12 months after drug-eluting stent (DES) placement. In patients undergoing urgent non-cardiac surgery during the first 4 to 6 weeks after BMS or DES placement, continue DAPT. In patients with stents undergoing surgery that requires discontinuation of the P2Y<sub>12</sub> inhibitor (eg, clopidogrel), continue aspirin and re-start the P2Y<sub>12</sub> inhibitor as soon as possible after surgery (ACC/AHA [Fleisher 2014]). In patients undergoing elective CABG, discontinue clopidogrel at least 5 days before procedure; when urgent CABG is necessary, the ACCF/AHA CABG guidelines recommend discontinuation for at least 24 hours prior to surgery (ACCF/AHA [Hillis 2011]). The ACCF/AHA STEMI guidelines recommend discontinuation for at least 24 hours prior to <i>on-pump</i> CABG if possible; <i>off-pump</i> CABG may be performed within 24 hours of clopidogrel administration if the benefits of prompt revascularization outweigh the risks of bleeding (ACCF/AHA [O'Gara 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery stents: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. Duration of therapy, in general, is determined by the type of stent placed (bare metal or drug eluting) and whether an ACS event was ongoing at the time of placement (ACC/AHA [Levine 2016]; AHA/ACC/SCAI/ACS/ADA [Grines 2007]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153651\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2B6 (weak), CYP2C8 (moderate), CYP2C9 (weak), OATP1B1/SLCO1B1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153600\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8921&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amodiaquine: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Amodiaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: CYP2B6 Inhibitors (Weak) may increase the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May diminish the therapeutic effect of Clopidogrel.<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cangrelor: May diminish the antiplatelet effect of Clopidogrel. More specifically, while the use of Cangrelor is expected to increase total platelet inhibition in patients who have previously received Clopidogrel, Cangrelor is expected to decrease binding of Clopidogrel metabolites to P2Y12 receptors and thus reduce the extent of irreversible platelet inhibition. Management: Avoid administration of clopidogrel until cangrelor infusion is discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a moderate CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to a risk for impaired clopidogrel effectiveness with such a combination, carefully consider the need for a strong CYP2C19 inhibitor in patients receiving clopidogrel. Monitor patients closely for evidence of a diminished response to clopidogrel.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C8 Substrates (High risk with Inhibitors): CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexlansoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider the anticipated risks and benefits of this combination. If combined, increased monitoring for bleeding is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May diminish the antiplatelet effect of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole: May diminish the antiplatelet effect of Clopidogrel. Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel prescribing information recommends avoiding concurrent use with esomeprazole. Rabeprazole or pantoprazole may be lower-risk alternatives to esomeprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May enhance the adverse/toxic effect of Clopidogrel. Specifically, the risk for bleeding may be increased. FluvoxaMINE may decrease serum concentrations of the active metabolite(s) of Clopidogrel.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Advise patients receiving clopidogrel to minimize consumption of grapefruit and grapefruit juice.  Consumption of three 200 mL glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lansoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Liposomal): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Liposomal) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): May diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: May diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Clopidogrel labeling recommends avoiding concurrent omeprazole due to a possible decrease in clopidogrel effectiveness. Rabeprazole or pantoprazole may be lower-risk alternatives to omeprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PACLitaxel (Conventional): Clopidogrel may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PACLitaxel (Protein Bound): Clopidogrel may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pantoprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: Clopidogrel may increase the serum concentration of Pioglitazone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RABEprazole: May decrease serum concentrations of the active metabolite(s) of Clopidogrel. Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: Clopidogrel may increase the serum concentration of Repaglinide.  Management: Avoid use of clopidogrel and repaglinide if possible; if the combination must be used, limit total repaglinide daily dose to no more than 4 mg. This is contraindicated in some non-US labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Clopidogrel may increase the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selexipag: CYP2C8 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Selexipag. CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Selexipag.  Management: If initiating selexipag in a patient on a moderate CYP2C8 inhibitor, consider a less frequent dosing regimen (ie, once daily). If initiating a moderate CYP2C8 inhibitor in a patient on selexipag, consider a selexipag dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Clopidogrel may enhance the anticoagulant effect of Warfarin. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153623\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Consumption of three 200 mL glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects. Management: Avoid or minimize the consumption of grapefruit or grapefruit juice (Holmberg, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153602\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343717\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Information related to use during pregnancy is limited (Bauer 2012; DeSantis 2011; Myers 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20471452\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if clopidogrel is present in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153614\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid or minimize the consumption of grapefruit juice (Holmberg, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153604\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of bleeding; hemoglobin and hematocrit periodically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153594\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Clopidogrel requires <i>in vivo</i> biotransformation to an active thiol metabolite. The active metabolite irreversibly blocks the P2Y<sub>12</sub> component of ADP receptors on the platelet surface, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet aggregation. Platelets blocked by clopidogrel are affected for the remainder of their lifespan (~7-10 days).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153610\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Inhibition of platelet aggregation (IPA): Dose-dependent:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300-600 mg loading dose: Detected within 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-100 mg/day: Detected by the second day of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peak effect: Time to maximal IPA: Dose-dependent: <b>Note:</b> Degree of IPA based on adenosine diphosphate (ADP) concentration used during light aggregometry:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300-600 mg loading dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">ADP 5 micromole/L: 20% to 30% IPA at 6 hours post administration (Montelescot, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">ADP 20 micromole/L: 30% to 37% IPA at 6 hours post administration (Montelescot, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-100 mg/day: ADP 5 micromole/L: 50% to 60% IPA at 5-7 days (Herbert, 1993) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Platelet aggregation and bleeding time gradually return to baseline after ~5 days after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid, well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Parent drug: 98%; Inactive metabolite (carboxylic acid derivative): 94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via esterase-mediated hydrolysis to a carboxylic acid derivative (inactive) and via CYP450-mediated (CYP2C19 primarily) oxidation to a thiol metabolite (active) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: ~6 hours; Thiol derivative (active metabolite): ~30 minutes; carboxylic acid derivative (inactive; main circulating metabolite): ~8 hours; <b>Note:</b> A clopidogrel radiolabeled study has shown that covalent binding to platelets accounts for 2% of radiolabel and has a half-life of 11 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~0.75 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Following administration of a single <sup>14</sup>C-labeled clopidogrel oral dose; radioactivity measured over 5 days: Urine (50%); feces (46%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153613\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Clopidogrel Bisulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (90): $625.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $762.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Plavix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (90): $696.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $928.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153615\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aclop (AT);</li>\n      <li>Actaclo (PH);</li>\n      <li>Agrelan (ES);</li>\n      <li>Antiplar (PH);</li>\n      <li>Antiplatt (ET);</li>\n      <li>Apolets (TH);</li>\n      <li>Arapamin (ES);</li>\n      <li>Artepid (ID);</li>\n      <li>Artheogrel (PH);</li>\n      <li>Ateplax (EC, PE);</li>\n      <li>Bidogrel (ZW);</li>\n      <li>Bilgrel (VN);</li>\n      <li>Caplor (VN);</li>\n      <li>Ceranade (KR);</li>\n      <li>Ceruvin (TH);</li>\n      <li>Clavix (MY);</li>\n      <li>Clentel (EC);</li>\n      <li>Clidorel (ID);</li>\n      <li>Clo V (KR);</li>\n      <li>Cloart (KR);</li>\n      <li>Clodel (IE);</li>\n      <li>Clodor (LB);</li>\n      <li>Clofix (TW);</li>\n      <li>Clogin (ID);</li>\n      <li>Clogrel (BD);</li>\n      <li>Clood (IL);</li>\n      <li>Clopacin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Clopex (QA);</li>\n      <li>Clopid (SY);</li>\n      <li>Clopidexcel (IL);</li>\n      <li>Clopidolut (VN);</li>\n      <li>Clopidrol (PH);</li>\n      <li>Clopilet (IN);</li>\n      <li>Clopimed (LK);</li>\n      <li>Clopimet (PH);</li>\n      <li>Clopiright (HK);</li>\n      <li>Clopistad (HK);</li>\n      <li>Clopitab (LK);</li>\n      <li>Clopivas (HK);</li>\n      <li>Clopivaz (PH);</li>\n      <li>Clopivid (HK, MY);</li>\n      <li>Cloprez (LK);</li>\n      <li>Clorel (BD);</li>\n      <li>Clotinil (TW);</li>\n      <li>Clotiz (PH);</li>\n      <li>Clovex (JO);</li>\n      <li>Clovix (MY);</li>\n      <li>Clovixx (TW);</li>\n      <li>Copalex (HK);</li>\n      <li>Copedina (VN);</li>\n      <li>Copegrel (VN);</li>\n      <li>Cotol (TW);</li>\n      <li>CPG (ID);</li>\n      <li>Curovix (KR);</li>\n      <li>Deplat (TW);</li>\n      <li>Deplatt (ET, SG, ZW);</li>\n      <li>Deviplat (MX);</li>\n      <li>Dogrel (BD);</li>\n      <li>Duopidogrel (MY);</li>\n      <li>Egitromb (BG, VN);</li>\n      <li>G Plus (SG);</li>\n      <li>Grepid (ES, HR, IE, MT, TR);</li>\n      <li>Gridokline (MY);</li>\n      <li>Hemaflow (PH);</li>\n      <li>Hogel (CO);</li>\n      <li>Insigrel (ID);</li>\n      <li>Iscover (AR, AT, AU, BE, BG, BR, CH, CZ, DE, DK, EE, ES, FR, GB, GR, HR, HU, IE, IT, LT, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR);</li>\n      <li>Kogrel (MY);</li>\n      <li>Kovix (KR);</li>\n      <li>Lopirel (HK, UA);</li>\n      <li>Maxgrel (KR);</li>\n      <li>Nabratin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Nafamedil (VN);</li>\n      <li>Noclot (PK);</li>\n      <li>Nogrel (PH);</li>\n      <li>Noklot (ET, PH);</li>\n      <li>Panagrel (PE);</li>\n      <li>Pedovex (AE, QA);</li>\n      <li>Piax (AU, NZ);</li>\n      <li>Pidogul (KR);</li>\n      <li>Plabic (KR);</li>\n      <li>Placta (ID, SG);</li>\n      <li>Pladogrel (ID);</li>\n      <li>Plagril (SG);</li>\n      <li>Plahasan (VN);</li>\n      <li>Plahryl (UA);</li>\n      <li>Plamed (KR);</li>\n      <li>Planor (TR);</li>\n      <li>PlaquEx (BG);</li>\n      <li>Platarex (HU);</li>\n      <li>Platless (SG);</li>\n      <li>Platogrix (ID);</li>\n      <li>Platohril (UA);</li>\n      <li>Plator (BD);</li>\n      <li>Platout (TW);</li>\n      <li>Plavitor (KR);</li>\n      <li>Plavix (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IS, IT, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Plavos (ID);</li>\n      <li>Plazep (UA);</li>\n      <li>Preto (KR);</li>\n      <li>Provic (KR);</li>\n      <li>Q.O.L. (KR);</li>\n      <li>Ravalgen (EC);</li>\n      <li>Shinclop (VN);</li>\n      <li>Simclovix (ID);</li>\n      <li>Stenvix (JO);</li>\n      <li>Talcom (CN);</li>\n      <li>Therodel (ID);</li>\n      <li>Troken (LB, MY);</li>\n      <li>Trombex (SK);</li>\n      <li>Vaclo (ID);</li>\n      <li>Vicafidt (MX);</li>\n      <li>Vivelon (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &quot;A Randomized, Blinded, Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE Steering Committee,&quot; <i>Lancet</i>, 1996, 348(9083):1329-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/8918275/pubmed\" target=\"_blank\" id=\"8918275\">8918275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, et al, &quot;Effect of Clopidogrel Added to Aspirin in Patients With Atrial Fibrillation,&quot; <i>N Engl J Med</i>, 2009, 360(20):2066-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/19336502/pubmed\" target=\"_blank\" id=\"19336502\">19336502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. <i>Lancet</i>. 2006;367(9526):1903-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16765759/pubmed\" target=\"_blank\" id=\"16765759\">16765759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adams HP, del Zoppo G, Alberts MJ, et al, &quot;Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups,&quot; <i>Stroke</i>, 2007, 38(5):1655-1711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/17431204/pubmed\" target=\"_blank\" id=\"17431204\">17431204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018;41(suppl 1): S86-S104. doi: 10.2337/dc18-S009.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/29222380/pubmed\" target=\"_blank\" id=\"29222380\">29222380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiolillo DJ, Gibson CM, Cheng S, et al, &ldquo;Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,&rdquo; <i>Clin Pharmacol Ther</i>, 2011, 89(1):65-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20844485/pubmed\" target=\"_blank\" id=\"20844485\">20844485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bal dit Sollier C, Mahe I, Berge N, et al. Reduced Thrombus Cohesion in an <i>ex vivo</i> Human Model of Arterial Thrombosis Induced by Clopidogrel Treatment: Kinetics of the Effect and Influence of Single and Double Loading-Dose Regimens. <i>Thromb Res</i>. 2003;111(1-2):19-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/14644074/pubmed\" target=\"_blank\" id=\"14644074\">14644074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basra SS, Tsai P, and Lakkis NM. Safety and Efficacy of Antiplatelet and Antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. <i>J Am Coll Cardiol</i>. 2011;58(22):2263-2269<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22093501/pubmed\" target=\"_blank\" id=\"22093501\">22093501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer ME, Bauer ST, Rabbani AB, et al, &quot;Peripartum Management of Dual Antiplatelet Therapy and Neuraxial Labor Analgesia After Bare Metal Stent Insertion for Acute Myocardial Infarction,&quot; <i>Anesth Analg</i>, 2012, 115(3):613-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22584549/pubmed\" target=\"_blank\" id=\"22584549\">22584549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berger PB, Bell MR, Rihal CS, et al, &quot;Clopidogrel Versus Ticlopidine After Intracoronary Stent Placement,&quot; <i>J Am Coll Cardiol</i>, 1999, 34(7):1891-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/10588199/pubmed\" target=\"_blank\" id=\"10588199\">10588199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertrand ME, Rupprecht HJ, Urban P, et al, &quot;Double-Blind Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination With Aspirin Compared With Ticlopidine in Combination With Aspirin After Coronary Stenting,&quot; <i>Circulation</i>, 2000, 102(6):624-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/10931801/pubmed\" target=\"_blank\" id=\"10931801\">10931801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Cryer BL, Contant CF, et al, &quot;Clopidogrel With or Without Omeprazole in Coronary Artery Disease,&quot; <i>N Engl J Med</i>, 2010, 363(20):1909-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20925534/pubmed\" target=\"_blank\" id=\"20925534\">20925534</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Fox KA, Hacke W, et al, &quot;Clopidogrel and Aspirin Versus Aspirin Alone for the Prevention of Atherothrombotic Events,&quot; <i>N Engl J Med</i>, 2006, 354(16):1706-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16531616/pubmed\" target=\"_blank\" id=\"16531616\">16531616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen ZM, Jiang LX, Chen YP, et al, &quot;Addition of Clopidogrel to Aspirin in 45,852 Patients With Acute Myocardial Infarction: Randomized Placebo-Controlled Trial. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group,&quot; <i>Lancet</i>, 2005, 366(9497):1607-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16271642/pubmed\" target=\"_blank\" id=\"16271642\">16271642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connolly SJ, Eikelboom JW, Ng J, et al; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. <i>Ann Intern Med</i>. 2011;155(9):579-586.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22041946/pubmed\" target=\"_blank\" id=\"22041946\">22041946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, et al, &quot;Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes,&quot; <i>N Engl J Med</i>, 2010, 363(10):930-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20818903/pubmed\" target=\"_blank\" id=\"20818903\">20818903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Santis M, De Luca C, Mappa I, et al, &quot;Clopidogrel Treatment During Pregnancy: A Case Report and a Review of Literature,&quot; <i>Intern Med</i>, 2011, 50(16):1769-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21841343/pubmed\" target=\"_blank\" id=\"21841343\">21841343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Desta Z, Zhao X, Shin JG, et al, &quot;Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism,&quot; <i>Clin Pharmacokinet</i>, 2002, 41(12):913-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/12222994/pubmed\" target=\"_blank\" id=\"12222994\">12222994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dewilde WJM, Oirbans, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. <i>Lancet</i>. 2013;381:1107-1115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/23415013/pubmed\" target=\"_blank\" id=\"23415013\">23415013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo; <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/23098967/pubmed\" target=\"_blank\" id=\"23098967\">23098967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi: 10.1161/CIR.0000000000000105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/25085962/pubmed\" target=\"_blank\" id=\"25085962\">25085962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frelinger AL 3rd, Lee RD, Mulford DJ, et al, &quot;A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers,&quot; <i>J Am Coll Cardiol</i>, 2012, 59(14):1304-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22464259/pubmed\" target=\"_blank\" id=\"22464259\">22464259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frere C, Cuisset T, Morange PE, et al, &quot;Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment with Clopidogrel in Acute Coronary Syndrome,&quot; <i>Am J Cardiol</i>, 2008, 101(8):1088-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/18394438/pubmed\" target=\"_blank\" id=\"18394438\">18394438</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilard M, Arnaud B, Cornily JC, et al, &quot;Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind Ocla (Omeprazole Clopidogrel Aspirin) Study,&quot; <i>J Am Coll Cardiol</i>, 2008, 51(3):256-60.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilard M, Arnaud B, Le Gal G, et al, &quot;Influence of Omeprazol on the Antiplatelet Action of Clopidogrel Associated to Aspirin,&quot; <i>J Thromb Haemost</i>, 2006, 4(11):2508-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grines CL, Bonow RO, Casey DE, et al, &quot;AHA/ACC/SCAI/ACS/ADA Science Advisory, Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients With Coronary Artery Stents. A Science Advisory From the American Heart Association, American College of Cardiology, Society of Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association With Representation from the American College of Physicians,&quot; <i>Circulation</i>, 2007, 115(6):813-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/17224480/pubmed\" target=\"_blank\" id=\"17224480\">17224480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herbert JM, Frehel D, Vallee E, et al, &quot;Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent,&quot; <i>Cardiovascular Drug Rev</i>, 1993, 11(2):180-98.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo; <i>Circulation </i>, 2006, 113(11):e463-654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16549646/pubmed\" target=\"_blank\" id=\"16549646\">16549646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ho PM, Maddox TM, Wang L, et al, &quot;Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome,&quot; <i>JAMA</i>, 2009, 301(9):937-44.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochholzer W, Trenk D, Fromm MF, et al, &quot;Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment with Clopidogrel in Patients Undergoing Elective Coronary Stent Placement,&quot; <i>J Am Coll Cardiol</i>, 2010, 55(22):2427-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20510210/pubmed\" target=\"_blank\" id=\"20510210\">20510210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochholzer W, Trenk D, Frundi D, et al, &quot;Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention,&quot; <i>Circulation</i>, 2005, 111(20):2560-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/15809367/pubmed\" target=\"_blank\" id=\"15809367\">15809367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmberg MT, Tornio A, Neuvonen M, et al. Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel.<i> Clin Pharmacol Ther</i>. 2013; Sept 25. Epub.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/24067745/pubmed\" target=\"_blank\" id=\"24067745\">24067745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holmes DR, Dehmer GJ, Kaul S, et al, &quot;ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA 'Boxed Warning.' A Report of the American College of Cardiology Foundation Task Force,&quot; <i>J Am Coll Cardiol</i>, 2010, 56(4):321-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20585015 /pubmed\" target=\"_blank\" id=\"20585015 \">20585015 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000041</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeske AH, Suchko GD, ADA Council on Scientific Affairs and Division of Science, et al, &ldquo;Lack of a Scientific Basis for Routine Discontinuation of Oral Anticoagulation Therapy Before Dental Treatment,&rdquo; <i>J Am Dent Assoc</i>, 2003, 134(11):1492-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/14664269 /pubmed\" target=\"_blank\" id=\"14664269 \">14664269 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juurlink DN, Gomes T, Ko DT, et al, &quot;A Population-Based Study of the Drug Interaction Between Proton Pump Inhibitors and Clopidogrel,&quot; <i>CMAJ</i>, 2009, 180(7):713-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/19176635/pubmed\" target=\"_blank\" id=\"19176635\">19176635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kastrati A, Mehilli J, Schuhlen H, et al, &quot;A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention After Pretreatment With Clopidogrel,&quot; <i>N Engl J Med</i>, 2004, 350(3):232-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/14724302/pubmed\" target=\"_blank\" id=\"14724302\">14724302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kreutz RP, Stanek EJ, Aubert R, et al, &quot;Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study,&quot; <i>Pharmacotherapy</i>, 2010, 30(8):787-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20653354/pubmed\" target=\"_blank\" id=\"20653354\">20653354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulik A, Ruel M, Jneid H, et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;131(10):927-964. doi: 10.1161/CIR.0000000000000182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/25679302/pubmed\" target=\"_blank\" id=\"25679302\">25679302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lange RA and Hillis LD, &quot;Antiplatelet Therapy for Ischemic Heart Disease,&quot; <i>N Engl J Med</i>, 2004, 350(3):277-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/14724308/pubmed\" target=\"_blank\" id=\"14724308\">14724308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Bittl JA, et al; Focused Update Writing Group. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online March 23, 2016]. <i>J Am Coll Cardiol</i>. pii: S0735-1097(16)01699-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/27036918/pubmed\" target=\"_blank\" id=\"27036918\">27036918</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lidell C, Svedberg LE, Lindell P, et al, &quot;Clopidogrel and Warfarin: Absence of Interaction in Patients Receiving Long-Term Anticoagulant Therapy for Nonvalvular Atrial Fibrillation,&quot; <i>Thromb Haemost</i>, 2003, 89(5):842-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/12719782/pubmed\" target=\"_blank\" id=\"12719782\">12719782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li XQ, Andersson TB, Ahalstr&ouml;m M, et al, &quot;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole and Rabeprazole on Human Cytochrome P450 Activities,&quot; <i>Drug Metab Dispo</i>, 2004, 32(8):821-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/15258107/pubmed\" target=\"_blank\" id=\"15258107\">15258107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lokhandwala J, Best PJ, Henry Y, Berger PB. Allergic reactions to clopidogrel and cross-reactivity to other agents. <i>Curr Allergy Asthma Rep</i>. 2011;11(1):52-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20941557/pubmed\" target=\"_blank\" id=\"20941557\">20941557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mauri L, Kereiakes DJ, Yeh RW, et al; the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents [published online ahead of print November 16, 2014]. <i>N Engl J Med</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/25399658/pubmed\" target=\"_blank\" id=\"25399658\">25399658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mega JL, Close SL, Wiviott SD, et al, &quot;Cytochrome P-450 Polymorphisms and Response to Clopidogrel,&quot; <i>N Engl J Med</i>, 2009, 360(40):354-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/19106084/pubmed\" target=\"_blank\" id=\"19106084\">19106084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mehta SR, Yusuf S, Peters RJ, et al, &quot;Effects of Pretreatment With Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study,&quot; <i>Lancet</i>, 2001, 358(9281):527-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/11520521/pubmed\" target=\"_blank\" id=\"11520521\">11520521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mishkel GJ, Aguirre FV, Ligon RW, et al, &quot;Clopidogrel as Adjunctive Antiplatelet Therapy During Coronary Stenting,&quot; <i>J Am Coll Cardiol</i>, 1999, 34(7):1884-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/10588198/pubmed\" target=\"_blank\" id=\"10588198\">10588198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montalescot G, Sideris G, Meuleman C, et al, &quot;A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes,&quot; <i>J Am Coll Cardiol</i>, 2006, 48(5):931-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16949482/pubmed\" target=\"_blank\" id=\"16949482\">16949482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moussa I, Oetgen M, Roubin G, et al, &quot;Effectiveness of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin in Preventing Stent Thrombosis After Coronary Stent Implantation,&quot; <i>Circulation</i>, 1999, 99(18):2364-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/10318654/pubmed\" target=\"_blank\" id=\"10318654\">10318654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muller C, Caillard S, Jesel L, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. <i>Am J Kidney Dis</i>. 2012;59(6):777-785.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22425260/pubmed\" target=\"_blank\" id=\"22425260\">22425260</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myers GR, Hoffman MK, and Marshall ES, &quot;Clopidogrel Use Throughout Pregnancy in a Patient With a Drug-Eluting Coronary Stent,&quot; <i>Obstet Gynecol</i>, 2011, 118(2 Pt 2):432-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21768844/pubmed\" target=\"_blank\" id=\"21768844\">21768844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Donoghue ML, Braunwald E, Antman EM, et al, &quot;Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel with or without a Proton-pump Inhibitor: an Analysis of Two Randomised Trials,&quot; <i>Lancet</i>, 2009, 374(9694):989-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/19726078/pubmed\" target=\"_blank\" id=\"19726078\">19726078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ogilvie BW, Yerino P, Kazmi F, et al, &ldquo;The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration With Clopidogrel,&rdquo; <i>Drug Metab Dispos</i>, 2011, 39(11):2020-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21795468/pubmed\" target=\"_blank\" id=\"21795468\">21795468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patti G, Colonna G, Pasceri V, et al, &quot;Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Study,&quot; <i>Circulation</i>, 2005, 111(16):2099-106.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21958886\"></a>Patti G, B&aacute;rczi G, Orlic D, et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2011;58(15),1592-1599.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21958886/pubmed\" target=\"_blank\" id=\"21958886\">21958886</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pezalla E, Day D, and Pulliadath I, &quot;Initial Assessment of Clinical Impact of a Drug Interaction Between Clopidogrel and Proton Pump Inhibitors,&quot; <i>J Am Coll Cardiol</i>, 2008, 52(12):1038-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plavix (clopidogrel) [prescribing information]. Bridgewater, NJ: Bristol-Myers Squibb; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plavix (clopidogrel) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Price MJ, Berger PB, Teirstein PS, et al, &quot;Standard- Vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial,&quot; <i>JAMA</i>, 2011, 305(11):1097-105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21406646/pubmed\" target=\"_blank\" id=\"21406646\">21406646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rooke TW, Hirsch AT, Misra S, et al, &ldquo;2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(18):2020-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21959305/pubmed\" target=\"_blank\" id=\"21959305\">21959305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sabatine MS, Cannon CP, Gibson CM, et al, &quot;Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction With ST-Segment Elevation,&quot; <i>N Engl J Med</i>, 2005, 352(12):1179-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/15758000/pubmed\" target=\"_blank\" id=\"15758000\">15758000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16143698\"></a>Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. <i>JAMA</i>. 2005b;294:(10)1224-1232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16143698/pubmed\" target=\"_blank\" id=\"16143698\">16143698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scirica BM, Sabatine MS, Morrow DA, et al, &quot;The Role of Clopidogrel in Early and Sustained Arterial Patency After Fibrinolysis for ST-segment Elevation Myocardial Infarction. The ECG Clarity-TIMI 28 Study,&quot; <i>J Am Coll Cardiol</i>, 2006, 48(1):37-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16814646/pubmed\" target=\"_blank\" id=\"16814646\">16814646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sibbing D, Koch W, Gebhard D, et al, &quot;Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement,&quot; <i>Circulation</i>, 2010, 121(4):512-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/20083681/pubmed\" target=\"_blank\" id=\"20083681\">20083681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siller-Matula JM, Spiel AO, Lang IM, et al, &quot;Effects of Pantoprazole and Esomeprazole on Platelet Inhibition by Clopidogrel,&quot; <i>Am Heart J</i>, 2009, 157(1):148.e1-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sim SC, Risinger C, Dahl ML, et al, &quot;A Common Novel CYP2C19 Gene Variant Causes Ultrarapid Drug Metabolism Relevant for the Drug Response to Proton Pump Inhibitors and Antidepressants,&quot; <i>Clin Pharmacol Ther</i>, 2006, 79(1):103-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/16413245/pubmed\" target=\"_blank\" id=\"16413245\">16413245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simon T, Bhatt DL, Bergougnan L, et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. <i>Clin Pharmacol Ther</i>. 2011;90(2):287-295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/21716274/pubmed\" target=\"_blank\" id=\"21716274\">21716274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Small DS, Farid NA, Payne CD, et al, &quot;Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel,&quot; <i>J Clin Pharmacol</i>, 2008, 48(4):475-84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    SPS3 Investigators, &ldquo;Effects of Clopidogrel Added to Aspirin in Patients With Recent Lacunar Stroke,&rdquo; <i>N Engl J Med</i>, 2012, 367(9):817-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22931315/pubmed\" target=\"_blank\" id=\"22931315\">22931315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinhubl SR, Berber PB, Mann JT, et al, &quot;Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. A Randomized Controlled Trial,&quot; <i>JAMA</i>, 2002, 288(19):2411-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/12435254/pubmed\" target=\"_blank\" id=\"12435254\">12435254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trenk D, Hochholzer W, Fromm MF, et al, &quot;Cytochrome P450 2C19 681G&gt;A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug Eluting or Bare-Metal Stents,&quot; <i>J Am Coll Cardiol</i>, 2008, 51(20):1925-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/18482659/pubmed\" target=\"_blank\" id=\"18482659\">18482659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Clopidogrel (Plavix): Dental Considerations of an Antiplatelet Drug,&rdquo; <i>Gen Dent</i>, 2001, 49(6):564-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/12024741 /pubmed\" target=\"_blank\" id=\"12024741 \">12024741 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yeh RW, Secemsky EA, Kereiakes DJ, et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention.<i> JAMA</i>. 2016;315(16):1735-1749.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/27022822/pubmed\" target=\"_blank\" id=\"27022822\">27022822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    You JJ, Singer DE, Howard PA, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 Suppl):S531-S575.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/22315271/pubmed\" target=\"_blank\" id=\"22315271\">22315271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yusuf S, Zhao F, Mehta SR, et al, &quot;Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes Without ST-Segment Elevation,&quot; <i>N Engl J Med</i>, 2001, 345(7):494-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clopidogrel-drug-information/abstract-text/11519503/pubmed\" target=\"_blank\" id=\"11519503\">11519503</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8921 Version 243.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10072956\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F153626\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50667916\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F153658\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F153630\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F153631\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F153632\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F153633\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F153606\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F153591\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11566548\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9480379\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F153608\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475278\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F153666\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F153598\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F153611\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F153595\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F153651\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F153600\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F153623\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F153602\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3343717\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20471452\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F153614\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F153604\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F153594\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F153610\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F153613\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F153615\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8921|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clopidogrel-patient-drug-information\" class=\"drug drug_patient\">Clopidogrel: Patient drug information</a></li><li><a href=\"topic.htm?path=clopidogrel-pediatric-drug-information\" class=\"drug drug_pediatric\">Clopidogrel: Pediatric drug information</a></li></ul></div></div>","javascript":null}